Engineered for Effectiveness; A next Generation ICS Molecule in Asthma

Wednesday, 1 May, 2019 13.00

Engineered for Effectiveness: a next generation ICS molecule in asthma

01-May-2019 at13:00


Join UK respiratory experts to explore a once daily medicine for Asthma patients

50 years of pharmacological improvements: why is asthma still a problem?
Does potency in inhaled corticosteroids pose greater benefit or risk for asthma patients?
How might you improve asthma control without increasing serious side effects in every day clinical practice?3

Regular inhaled corticosteroid (ICS) therapy is the cornerstone of asthma management and central to enabling people with asthma to lead normal lives free from symptoms. However, suboptimal adherence to regular maintenance therapy remains a key barrier to patients achieving optimal asthma control. Fluticasone furoate was designed as a next generation inhaled corticosteroid molecule, developed to improve on the success of our previous inhaled steroids and improve asthma control.1,2,3

(Fluticasone furoate not licensed as a Monotherapy)


1. Daley-Yates PT. Br J Clin Pharmacol. 2015; 80: 372–380
2. GSK. Relvar Ellipta Summary of Product Characteristics 2018
3. Woodcock A et al. Lancet. 2017;390: 2247-2255

Register now to secure your place here —-> CLICK HERE

View all events >

LPC EGM to amend constitution

This special meeting of contractors is being called to amend the LPC Constitution to allow the Committee to delay the...

Diabetes event with Dr Duncan Browne

Dear Pharmacist Please find attached  invite  for an evening  On-line Diabetes presentation  with Lead Diabetes  Consultant , Dr Duncan Browne...

Making the most of eRD Webinar

The South West and West of England AHSNs are inviting community pharmacists to a webinar entitled ‘Making the most of...